Prosecution Insights
Last updated: April 19, 2026
Application No. 18/517,961

STENT WITH SELECTIVE MEMBRANE COATING

Non-Final OA §102§103
Filed
Nov 22, 2023
Examiner
LABRANCHE, BROOKE N
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
BOSTON SCIENTIFIC CORPORATION
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
3y 1m
To Grant
87%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allow Rate
326 granted / 448 resolved
+2.8% vs TC avg
Moderate +15% lift
Without
With
+14.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
72 currently pending
Career history
520
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
45.2%
+5.2% vs TC avg
§102
29.5%
-10.5% vs TC avg
§112
20.7%
-19.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 448 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-15, 17, and 18 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Folan et al. (US 2021/0015598). Regarding claim 1, Folan et al. discloses an expandable medical device (400, 500, or 600, FIGs 4A, 5A, 6A), comprising: a tubular scaffold (402, 502, 602), the tubular scaffold including an inner surface (Side facing lumen), an outer surface (Radially outer surface), a proximal end region (406 and right side of 500 and 600), a distal end region (404 and left side of 500 and 600), a lumen extending from the proximal end region to the distal end region (405, [0055], and respective lumens of 500 and 600), and a portion of the tubular scaffold defining a retention member extending radially away from the outer surface (440, [0056-0059], 540, [0060], and 640, [0061]) wherein the retention member has a distally facing surface (Left side of the retention member) and a proximally facing surface (Right side of the retention member); and a membrane (420, [0055 and 0057], 520, [0060], and 620, [0061]) disposed within the lumen of the tubular scaffold ([0057] and see FIGs 4A, 5A, 6A; the membrane is within the lumen of the scaffold); wherein the membrane is secured to the inner surface of the tubular scaffold at a first circumferential attachment region (At least some point of contact of the membrane to the scaffolding at the distal end of the device. At least cross sections FIG 5B and 6B show the membrane attaches in the circumferential direction due to the tubular shape. FIGs 4A, 5A, and 6A show different embodiment of attachment points where the figures show whether the membrane is in contact with the scaffold or spaced apart. See rejection below for specific indication of first circumferential attachment region), and wherein the membrane is secured to the inner surface of the tubular scaffold at a second circumferential attachment region (At least some point of contact of the membrane to the scaffolding at a more proximal end of the device. See rejection below for specific indication of first circumferential attachment region); wherein the membrane is unattached to the inner surface of the tubular scaffold between the first circumferential attachment region and the second circumferential attachment region (FIGs 4A, 5A, and 6A each show region of unattached membrane) to define a tissue ingrowth region between the inner surface of the tubular scaffold and an outwardly-facing surface of the membrane (The pocket created between the outer surface at the unattached membrane position and the inner surface of the scaffolding creates a region configured to allow tissue ingrowth, [0057, 0060, 0061]). Regarding claim 2, Folan et al. discloses the membrane is configured to maintain a passageway therethrough (The membrane maintains the shape of the lumen which acts as a passageway through the device). Regarding claim 3, Folan et al. discloses tissue ingrowth region extends circumferentially around the inner surface of the tubular scaffold (See FIG 4A where the ingrowth region at 435 extends circumferentially around the scaffolding). Regarding claim 4, Folan et al. discloses the membrane is formed from an elastic material ([0046]). Regarding claim 5, Folan et al. discloses the membrane is designed to permit tissue ingrowth between the inner surface of the tubular scaffold and an outwardly-facing surface of the membrane ([0046, 0056-0057, 0060-0061], FIGs show the ingrowth pocket is formed between the outer surface of the membrane and inner surface of the scaffolding) Regarding claim 6, Folan et al. discloses the first circumferential attachment region is secured to the inner surface of the tubular scaffold along the distal end region and wherein the second circumferential attachment region is secured to the inner surface of the tubular scaffold at a position distal to the retention member (See annotated FIG 4A below). PNG media_image1.png 297 530 media_image1.png Greyscale Regarding claim 7, Folan et al. discloses the tubular scaffold includes interstices extending from the outer surface of the tubular scaffold to the inner surface of the tubular scaffold ([0046] describes the interstices of the scaffold), and wherein the membrane spans the interstices of the portion of the tubular scaffold which defines the retention member (The membrane spans the interstices of the retention member 440 because 420 does not directly contact 440 but instead spans the gap across). Regarding claim 8, Folan et al. discloses the tubular scaffold includes interstices extending from the outer surface of the tubular scaffold to the inner surface of the tubular scaffold ([0046] describes the interstices of the scaffold), and wherein the membrane encapsulates the interstices of the portion of the tubular scaffold which defines the retention member (The membrane encapsulates this portion by creating a pocket between the membrane and the scaffold of the retention member). Regarding claim 9, Folan et al. discloses the first circumferential attachment region is secured to the inner surface of the tubular scaffold along the distal end region and wherein the second circumferential attachment region is secured to the inner surface of the tubular scaffold at a position proximal to the retention member (See annotated FIG 4A below). PNG media_image2.png 292 526 media_image2.png Greyscale Regarding claim 10, Folan et al. discloses the tubular scaffold includes interstices extending from the outer surface of the tubular scaffold to the inner surface of the tubular scaffold ([0046] describes the interstices of the scaffold), wherein tissue is permitted to grow through the interstices of the portion of the tubular scaffold between the first circumferential attachment region and the second circumferential attachment region (Tissue is permitted to grow at least in the pocket created at the region of 440, which is positioned between the first and second circumferential attachment region as claimed). Regarding claim 11, Folan et al. discloses the distal end region of the tubular scaffold further includes a flared portion (425, [0057], also shown but not numbered in FIG 5A and 6A). Regarding claim 12, Folan et al. discloses the first circumferential attachment region is secured to the inner surface of the tubular scaffold at a position proximal to the flared portion and wherein the second circumferential attachment region is secured to the inner surface of the tubular scaffold at a position distal to the retention member (See annotated FIG 5A below). PNG media_image3.png 370 417 media_image3.png Greyscale Regarding claim 13, Folan et al. discloses the membrane is in direct contact with the inner surface of the portion of the tubular scaffold defining the retention member (See bottom side of 540 on FIG 5A and 5B wherein the membrane directly contacts and follows the contour of the retention member). Regarding claim 14, Folan et al. discloses the flared portion includes interstices extending from the outer surface of the tubular scaffold to the inner surface of the tubular scaffold ([0046] describes the interstices of the scaffold), wherein the flared portion is devoid of the membrane such that tissue is permitted to grow through the interstices of the tubular scaffold along the flared portion (FIG 5A shows the membrane is not in direct contact with the flared portion, thereby creating a pocket/space therebetween which allows for tissue ingrowth). Regarding claim 15, Folan et al. discloses the retention member has a diameter (Widened diameter taken at 540 in FIG 5A), wherein the flared portion has a diameter (Any diameter taken along the tapered flared section), and wherein the diameter of the retention member is greater than the diameter of the flared portion (FIG 5A shows the retention member has a greater diameter than at least some smaller diameter taken along the tapered region of the flared portion). Regarding claim 17, Folan et al. discloses the membrane is further secured to the inner surface of the tubular scaffold at a plurality of spaced-apart discrete attachment points positioned between the first circumferential attachment region and the second circumferential attachment region (See annotated FIG 6A below). PNG media_image4.png 257 520 media_image4.png Greyscale Regarding claim 18, Folan et al. discloses regions of the membrane between the plurality of spaced-apart discrete attachment points are radially spaced from the inner surface of the tubular scaffold (FIG 6A), creating a plurality of tissue ingrowth regions positioned between the first circumferential attachment region and the second circumferential attachment region (635, [0061]). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 16, 19, and 20 are rejected under 35 U.S.C. 103 as being unpatentable over Folan et al. (US 2021/0015598). Regarding claims 16, 19, and 20, Folan et al. discloses an expandable medical device (400, 500, or 600, FIGs 4A, 5A, 6A), comprising: a tubular scaffold (402, 502, 602), the tubular scaffold including an inner surface (Side facing lumen), an outer surface (Radially outer surface), a proximal end region (406 and right side of 500 and 600), a distal end region (404 and left side of 500 and 600)including a flared portion (425, [0057], also shown but not numbered in FIG 5A and 6A), a lumen extending from the proximal end region to the distal end region (405, [0055], and respective lumens of 500 and 600), and a retention member extending radially away from the outer surface (440, [0056-0059], 540, [0060], and 640, [0061]) wherein the retention member has a distally facing surface (Left side of the retention member) and a proximally facing surface (Right side of the retention member); and a membrane (420, [0055 and 0057], 520, [0060], and 620, [0061]) disposed within the lumen of the tubular scaffold ([0057] and see FIGs 4A, 5A, 6A; the membrane is within the lumen of the scaffold); wherein the membrane is secured to the inner surface of the tubular scaffold at a first circumferential attachment region (At least some point of contact of the membrane to the scaffolding at the distal end of the device. At least cross sections FIG 5B and 6B show the membrane attaches in the circumferential direction due to the tubular shape. FIGs 4A, 5A, and 6A show different embodiment of attachment points where the figures show whether the membrane is in contact with the scaffold or spaced apart. See rejection above for specific indication of first circumferential attachment region), and wherein the membrane is secured to the inner surface of the tubular scaffold at a second circumferential attachment region (At least some point of contact of the membrane to the scaffolding at a more proximal end of the device. See rejection above for specific indication of first circumferential attachment region); wherein the membrane is configured to maintain a passageway therethrough (The membrane maintains the shape of the lumen which acts as a passageway through the device); wherein the flared portion includes interstices extending from the outer surface of the tubular scaffold to the inner surface of the tubular scaffold ([0046] describes the interstices of the scaffold), wherein the flared portion is devoid of the membrane such that tissue is permitted to grow through the interstices of the tubular scaffold along the flared portion (FIG 5A shows the membrane is not in direct contact with the flared portion, thereby creating a pocket/space therebetween which allows for tissue ingrowth). Folan et al. is silent regarding the distally facing surface being positioned substantially parallel to the proximally facing surface. However, Folan et al. discloses in FIGs 4A-4E a variety of different shapes that can be formed by the retention member including spherical, trapezoidal, pentagonal, and chordal ([0058]) Folan further discloses “Embodiments herein are not limited in this context”. Therefore, it would have been an obvious matter of design choice to modify the cross sectional shape of the retention member to be rectangular or square, thereby providing a distally facing surface that is substantially parallel to the proximally facing surface, since such a modification would have involved a mere change in the form or shape of a component. A change in form or shape is generally recognized as being within the level of ordinary skill in the art. In re Dailey, 149 USPQ47 (CCPA 1976). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BROOKE N LABRANCHE whose telephone number is (571)272-9775. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Elizabeth Houston can be reached at 5712727134. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BROOKE LABRANCHE/Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Nov 22, 2023
Application Filed
Feb 24, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599395
SURGICAL FORCEPS AND FIXATION THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12594080
Medical Device for Causing Hemostasis of Blood Vessel
2y 5m to grant Granted Apr 07, 2026
Patent 12582429
MEDICAL APPARATUS WITH OPTICAL SENSING, AND RELATED DEVICES AND METHODS
2y 5m to grant Granted Mar 24, 2026
Patent 12582512
METHOD FOR FORMING PTFE COATING FILM ON STENT, AND STENT MANUFACTURED THEREBY
2y 5m to grant Granted Mar 24, 2026
Patent 12582550
Determining Fluid Flow Rate in a Phacoemulsification Probe
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
87%
With Interview (+14.6%)
3y 1m
Median Time to Grant
Low
PTA Risk
Based on 448 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month